

Hypoactive Sexual Desire Disorder (HSDD) - Pipeline Insight, 2019

<https://marketpublishers.com/r/HFF8FE31921EN.html>

Date: August 2019

Pages: 60

Price: US\$ 1,250.00 (Single User License)

ID: HFF8FE31921EN

Abstracts

This report can be delivered to the clients within 24 Hours

"Hypoactive Sexual Desire Disorder (HSDD) - Pipeline Insight, 2019" report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Hypoactive Sexual Desire Disorder pipeline landscape is provided which includes the disease overview and Hypoactive Sexual Desire Disorder treatment guidelines. The assessment part of the report embraces, in depth Hypoactive Sexual Desire Disorder commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Hypoactive Sexual Desire Disorder collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Hypoactive Sexual Desire Disorder Understanding

"Hypoactive sexual desire disorder (HSDD) or inhibited sexual desire (ISD) is the condition defined as the absence of sexual fantasies and thoughts, and/or desire for or receptivity to, sexual activity. This receptivity leads to stress and cause the personal distress and interpersonal difficulties. There are a number of potential physical and psychological factors behind this condition. Physical conditions like breast cancer, diabetes, depression, urinary incontinence, thyroid problems are associated with HSDD. Neurotransmitter imbalance may also inhibit the sexual desire and excitement. Psychological factors like depression, anxiety, and low self-esteem also play major role in diminished libido. The evaluation of HSDD generally requires careful consideration of the patient and the multitude of factors that impact the various components of adult

female sexual desire. Despite over three decades since its definition and multiple changes in an attempt to improve the accuracy of the diagnosis, established treatment paradigms are lacking. Treatment for HSDD involves assessment of history and symptoms, Sex therapy (which has been the standard treatment for HSDD for a long time), Testosterone treatment (Menopausal women with HSDD).

Hypoactive Sexual Desire Disorder (HSDD) Pipeline Development Activities

The report provides insights into different therapeutic candidates in discovery and preclinical, phase 1, phase 2, and phase 3 stage. Drugs under development as a monotherapy or combination therapy are also included. It also analyses key players involved in Hypoactive Sexual Desire Disorder targeted therapeutics development with respective active and inactive (dormant or discontinued) projects with the appropriate reasons if available. Hypoactive Sexual Desire Disorder pipeline report covers 5+ companies. Some of the key players include Emotional Brain (Sildenafil/testosterone), Palatin Technologies (Bremelanotide) etc.

The report is built using data and information traced from the researcher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university web sites and industry-specific third party sources, etc.

Hypoactive Sexual Desire Disorder (HSDD) Analytical Perspective by DelveInsight

In-depth Hypoactive Sexual Desire Disorder Commercial Assessment of products

This report provides an in-depth Commercial Assessment of therapeutic drugs have been included which comprises of collaborations, Licensing, Acquisition –Deal Value Trends. The sub-segmentation is described in the report which includes Company-Company Collaborations (Licensing / Partnering), Company-Academia Collaborations, and Acquisition analysis in both Graphical and tabulated form.

Hypoactive Sexual Desire Disorder Clinical Assessment of products

The report comprises of comparative clinical assessment of products by development stage, product type, route of administration, molecule type, and MOA type across this

indication.

Scope of the report

The Hypoactive Sexual Desire Disorder report provides an overview of therapeutic pipeline activity for Hypoactive Sexual Desire Disorder across the complete product development cycle including all clinical and non-clinical stages

It comprises of detailed profiles of Hypoactive Sexual Desire Disorder therapeutic products with key coverage of developmental activities including technology, collaborations, licensing, mergers and acquisition, funding, designations and other product related details

Detailed Hypoactive Sexual Desire Disorder Research and Development progress and trial details, results wherever available, are also included in the pipeline study

Therapeutic assessment of the active pipeline products by development stage, product type, route of administration, molecule type, and MOA type

Coverage of dormant and discontinued pipeline projects along with the reasons if available across Hypoactive Sexual Desire Disorder

Reasons to Buy

Establish a comprehensive understanding of the current pipeline scenario across Hypoactive Sexual Desire Disorder to formulate effective R&D strategies

Assess challenges and opportunities that influence Hypoactive Sexual Desire Disorder R&D

Develop strategic initiatives by understanding the focus areas of leading companies.

Gather impartial perspective of strategies of the emerging competitors having potentially lucrative portfolio in this space and create effective counter strategies to gain competitive advantage

Get in detail information of each product with updated information on each project along with key milestones

Devise Hypoactive Sexual Desire Disorder in licensing and out licensing strategies by identifying prospective partners with progressing projects for Hypoactive Sexual Desire Disorder to enhance and expand business potential and scope

Our extensive domain knowledge on therapy areas support the clients in decision-making process regarding their therapeutic portfolio by identifying the reason behind the inactive or discontinued drugs

Contents

1. REPORT INTRODUCTION

2. HYPOACTIVE SEXUAL DESIRE DISORDER (HSDD) (INHIBITED SEXUAL DESIRE (ISD))

2.1. Hypoactive Sexual Desire Disorder Disease Overview

2.2. Hypoactive Sexual Desire Disorder History

2.3. Hypoactive Sexual Desire Disorder Symptoms

2.4. Hypoactive Sexual Desire Disorder Causes

2.5. Hypoactive Sexual Desire Disorder Pathophysiology

2.6. Hypoactive Sexual Desire Disorder Diagnosis

2.6.1. Diagnostic Guidelines

3. HYPOACTIVE SEXUAL DESIRE DISORDER (HSDD) CURRENT TREATMENT PATTERNS

3.1. Treatment Guidelines

4. HYPOACTIVE SEXUAL DESIRE DISORDER (HSDD)- DELVEINSIGHT'S ANALYTICAL PERSPECTIVE

4.1. In-depth Commercial Assessment

4.1.1. Hypoactive Sexual Desire Disorder companies collaborations, Licensing, Acquisition –Deal Value Trends

4.1.1.1. Assessment Summary

4.1.2. Hypoactive Sexual Desire Disorder Collaboration Deals

4.1.2.1. Company-Company Collaborations (Licensing / Partnering) Analysis

4.1.2.2. Hypoactive Sexual Desire Disorder Acquisition Analysis

4.2. Clinical Assessment of Pipeline Drugs

4.2.1. Assessment by Phase of Development

4.2.2. Assessment by Product Type (Mono / Combination)

4.2.2.1. Assessment by Stage and Product Type

4.2.3. Assessment by Route of Administration

4.2.3.1. Assessment by Stage and Route of Administration

4.2.4. Assessment by Molecule Type

4.2.4.1. Assessment by Stage and Molecule Type

4.2.5. Assessment by MOA

4.2.5.1. Assessment by Stage and MOA

5. HYPOACTIVE SEXUAL DESIRE DISORDER PIPELINE THERAPEUTICS

5.1. Late Stage Products (Phase-III)

5.1.1. Comparative Analysis

5.2. Mid Stage Products (Phase-II)

5.2.1. Comparative Analysis

5.3. Early Stage Products (Phase-I)

5.3.1. Comparative Analysis

5.4. Pre-clinical and Discovery Stage Products

5.4.1. Comparative Analysis

5.5. Inactive Products

6. HYPOACTIVE SEXUAL DESIRE DISORDER-PRODUCTS ANALYSIS

6.1. Product Profiles

6.1.1. Sildenafil/testosterone- Emotional Brain

6.1.1.1. Product Description

6.1.1.1.1. Product Overview

6.1.1.1.2. Mechanism of Action

6.1.1.2. Research and Development

6.1.1.2.1. Clinical Studies

6.1.1.2.1.1. Detailed Study Description

6.1.1.2.1.2. Study Results

6.1.1.2.1.3. Clinical Trials: Tabular View

6.1.1.3. Product Development Activities

6.1.1.3.1. Tabulated Product Summary

6.1.1.3.1.1. General Description Table

6.1.2. Bremelanotide- Palatin Technologies

6.1.2.1. Product Description

6.1.2.1.1. Product Overview

6.1.2.1.2. Mechanism of Action

6.1.2.2. Research and Development

6.1.2.2.1. Clinical Studies

6.1.2.2.1.1. Detailed Study Description

6.1.2.2.1.2. Study Results

6.1.2.2.1.3. Clinical Trials: Tabular View

6.1.2.3. Product Development Activities

6.1.2.3.1. Tabulated Product Summary

6.1.2.3.1.1. General Description Table

To be continued in the report.....

7. RECENT TECHNOLOGIES

8. HYPOACTIVE SEXUAL DESIRE DISORDER KEY COMPANIES

8.1. Fabre-Kramer Pharmaceuticals

8.2. S1 Pharmaceuticals

8.3. Valeant Pharmaceuticals International

8.4. Emotional Brain

8.5. Palatin Technologies

9. HYPOACTIVE SEXUAL DESIRE DISORDER KEY PRODUCTS

9.1. TGFK 09SD

9.2. Bupropion/trazodone

9.3. SPT 201

9.4. Sildenafil/testosterone

9.5. Bremelanotide

9.6. Bupirone/testosterone

10. DORMANT AND DISCONTINUED PRODUCTS

10.1. Dormant Products

10.1.1. Reasons for being dormant

10.2. Discontinued Products

10.2.1. Reasons for the discontinuation

11. HYPOACTIVE SEXUAL DESIRE DISORDER- UNMET NEEDS

12. HYPOACTIVE SEXUAL DESIRE DISORDER- FUTURE PERSPECTIVES

13. APPENDIX

14. REPORT METHODOLOGY

14.1. Secondary Research

14.2. Expert Panel Validation

List Of Tables

LIST OF TABLES

- Table 1. Hypoactive Sexual Desire Disorder Diagnostic Guidelines
- Table 2. Treatment Guidelines
- Table 3. Assessment Summary
- Table 4. Company-Company Collaborations (Licensing / Partnering) Analysis
- Table 5. Hypoactive Sexual Desire Disorder Acquisition Analysis
- Table 6. Assessment by Phase of Development
- Table 7. Assessment by Product Type (Mono / Combination)
- Table 8. Assessment by Stage and Product Type
- Table 9. Assessment by Route of Administration
- Table 10. Assessment by Stage and Route of Administration
- Table 11. Assessment by Molecule Type
- Table 12. Assessment by Stage and Molecule Type
- Table 13. Assessment by MOA
- Table 14. Assessment by Stage and MOA
- Table 15. Late Stage Products (Phase-III)
- Table 16. Mid Stage Products (Phase-II)
- Table 17. Early Stage Products (Phase-I)
- Table 18. Pre-clinical and Discovery Stage Products
- Table 19. Inactive Products
- Table 20. Dormant Products
- Table 21. Discontinued Products

List Of Figures

LIST OF FIGURES

- Figure 1. Disease Overview
- Figure 2. History
- Figure 3. Symptoms
- Figure 4. Causes
- Figure 5. Pathophysiology
- Figure 6. Diagnostic Guidelines
- Figure 7. Treatment Guidelines
- Figure 8. Hypoactive Sexual Desire Disorder companies collaborations, Licensing, Acquisition –Deal Value Trends
- Figure 9. Company-Company Collaborations (Licensing / Partnering) Analysis
- Figure 10. Hypoactive Sexual Desire Disorder Acquisition Analysis
- Figure 11. Assessment by Phase of Development
- Figure 12. Assessment by Product Type (Mono / Combination)
- Figure 13. Assessment by Stage and Product Type
- Figure 14. Assessment by Route of Administration
- Figure 15. Assessment by Stage and Route of Administration
- Figure 16. Assessment by Molecule Type
- Figure 17. Assessment by Stage and Molecule Type
- Figure 18. Assessment by MOA
- Figure 19. Assessment by Stage and MOA
- Figure 20. Late Stage Products (Phase-III)
- Figure 21. Mid Stage Products (Phase-II)
- Figure 22. Early Stage Products (Phase-I)
- Figure 23. Pre-clinical and Discovery Stage Products
- Figure 24. Inactive Products
- Figure 25. Dormant Products
- Figure 26. Discontinued Products
- Figure 27. Unmet Needs

KEY COMPANIES

Fabre-Kramer Pharmaceuticals
Sprout Pharmaceuticals
S1 Pharmaceuticals
Valeant Pharmaceuticals International

Emotional Brain
Palatin Technologies
Endoceutics

I would like to order

Product name: Hypoactive Sexual Desire Disorder (HSDD) - Pipeline Insight, 2019

Product link: <https://marketpublishers.com/r/HFF8FE31921EN.html>

Price: US\$ 1,250.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/HFF8FE31921EN.html>